Research and Management of Endocrine Tumors

Dear Colleagues,

Endocrine tumors continue to be a problem for many patients all over the world.  In particular, thyroid cancer has has a significant increase in incidence and prevalence in recent years. Thyroid cancer is the most common endocrine cancer. In many cases, it is a benign form of malignancy. However, there are many cases of thyroid cancer that present with metastatic progressive disease. In these cases, novel therapeutic agents are applied, called multiple kinase inhibitors. Since their discovery, these therapeutic agents have offered new hope for patients with progressive metastatic disease. As the pathophysiology and prognosis of thyroid cancer becomes better understood, the indications for treatment with radioiodine will change. Treatment with radioiodine, its indications, and procedural changes will be upgraded as our understanding of thyroid cancer biology and pathophysiology improves. Adrenal cancer is also a medical problem that poses diagnostic and therapeutic challenges for physicians and biologists alike. With applying diagnostic methods like computer tomography and magnetic resonance imaging, the discovery of adrenal masses becomes increasingly easy. However, most of these endocrine neoplasms are benign. The differential diagnosis of a possible adrenal cancer as well as its treatment pose a diagnostic and therapeutic problem with major interest.

We look forward to receiving your contributions.

Dr. Ifigenia Kostoglou-Athanassiou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.